Novavax (Novavax) Long-Term Capital Lease Obligation

: $55.9 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

Novavax's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $55.9 Mil.

Novavax's quarterly Long-Term Capital Lease Obligation increased from Jun. 2023 ($30.7 Mil) to Sep. 2023 ($53.2 Mil) and increased from Sep. 2023 ($53.2 Mil) to Dec. 2023 ($55.9 Mil).

Novavax's annual Long-Term Capital Lease Obligation increased from Dec. 2021 ($0.0 Mil) to Dec. 2022 ($31.2 Mil) and increased from Dec. 2022 ($31.2 Mil) to Dec. 2023 ($55.9 Mil).

Novavax Long-Term Capital Lease Obligation Historical Data

The historical data trend for Novavax's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

40.08

31.24

55.92

Novavax Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															31.24	30.99	30.74	53.16	55.92

Novavax (NAS:NVAX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Novavax Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Novavax's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax (Novavax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (NAS:NVAX) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

NVAX:Mexico NVV1:Germany

Address

21 Firstfield Road, Gaithersburg, MD, USA, 20878

Website

https://www.novavax.com

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Executives

Filip Dubovsky	officer: President, R&D	C/O NOVAVAX INC., 21 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Gregory M Glenn	officer: President, R&D	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
Elaine O'hara	officer: EVP, Chief Strategy Officer	333 NORTH WARREN AVENUE, MALVERN PA 19355
John C Jacobs	director, officer: President and CEO	630 W. GERMANTOWN PIKE, SUITE 215, PLYMOUTH MEETING PA 19462
Richard J Rodgers	director	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
James F Young	director	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Herrmann John A Iii	officer: SVP, General Counsel	C/O NOVAVAX, INC., 20 FIRSTFIELD ROAD, GAITHERSBURG MD 20878
Stanley C Erck	director, officer: President and CEO	20 FIRSTFIELD ROAD, #250, GAITHERSBURG MD 20878
John Trizzino	officer: SVP, CBO and CFO	9920 BELWARD CAMPUS DRIVE, ROCKVILLE MD 20850
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
James Patrick Kelly	officer: EVP, CFO and Treasurer	C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gary C Evans	director	1048 TEXAN TRAIL, GRAPEVINE TX 76051
Rachel K. King	director	C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Mcmanus Michael A Jr	director	241-02 NORTHERN BLVD, DOUGLASTON NY 11362
Margaret G Mcglynn	director	C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100